Orphan Drugs

Everything

Elesclomol Granted Orphan Drug Status
www.dddmag.com
GlaxoSmithKline and Synta Pharmaceuticals Corp. announced that the US Food and Drug Administration has granted orphan drug designation to elesclomol (formerly STA-4783) for the treatment of patients with metastatic melanoma.

New Report Highlights Keys to European Market Access for Orphan Drugs | PRLog
www.prlog.org | Jul 7, 2011
New Report Highlights Keys to European Market Access for Orphan Drugs. Orphan Drugs in Europe: Pricing, Reimbursement, Funding & Market Access, 2011 Edition is a fully revised and greatly enlarged version of the best-selling 2008 report, and Don Macarthur’s fifth major title on orphan drugs. -

S*BIO | Pharma Asia
www.pharmaasia.com | Nov 4, 2010
November 4, 2010 Home About Us Current Issue Archives Events RSS Feeds More Advertising Information Editorial Information Technical Channels Drug Discovery Drug Development Drug Manufacturing Drug Delivery Clinical Trials

Aastrom Biosciences, Inc. - Aastrom Biosciences Receives Orphan Drug Designation from the FDA for
www.aastrom.com
Print E-mail PDF Add to briefcase Share this on: Close window delicious delicious Digg Digg Facebook Facebook LinkedIn LinkedIn Mixx Mixx Twitter Twitter Yahoo Buzz Yahoo! Buzz What is this? « Previous Release | Next Release » Aastrom Biosciences, Inc. March 23, 2006 Aastrom Biosciences Receives

FDA Approves Aastrom Phase III IND for Treatment of Osteonecrosis of the Femoral Head (NASDAQ:ASTM)
investors.aastrom.com
Print Email PDF Add to Briefcase Share this on: Close window delicious delicious Digg Digg Facebook Facebook LinkedIn LinkedIn Twitter Twitter Yahoo Buzz Yahoo! Buzz What is this? « Previous Release | Next Release » Aastrom Biosciences, Inc. May 7, 2007 FDA Approves Aastrom Phase III IND for

Lexicon Recieves Orphan Drug Designation For LX1032 - Pharmaceutical Business Review : News
www.pharmaceutical-business-review.com | Jul 21, 2009
LX1032, for managing gastrointestinal symptoms associated with carcinoid syndrome

Axentis Pharma AG's Cystic Fibrosis Liposomal Tobramycin Receives Second Orphan Drug Designation
www.biospace.com | Jul 16, 2009
<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img

Human Genome: Benlysta Gets FDA Nod - Seeking Alpha
seekingalpha.com | Mar 10, 2011
<strong><a href='http://vfcsstockhouse.blogspot.com/'>VFC</a>submits:</strong><p>The long wait is over for<strong>Human Genome Sciences (<a href='http://seekingalpha.com/symbol/hgsi' title='Human Genome Sciences Inc.'>HGSI</a>)</strong>, partner GlaxoSmithKline (<a

Medical News: FDA Expands Agent's Orphan Drug Status - in Product Alert, Prescriptions from MedPage
www.medpagetoday.com | Nov 5, 2009
WASHINGTON -- The FDA has extended the orphan drug status of the breast cancer agent protein-bound paclitaxel (Abraxane) for use in stage IIB-IV melanoma treatment.

News: Callisto Pharmaceuticals Granted Orphan Drug Designation for its Candidate against Carcinoid
www.genengnews.com
Callisto Pharmaceuticals has been granted orphan drug designation for Atiprimod, its drug candidate for carcinoid tumors. Atiprimod is a small molecule orally available drug with a